FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 651 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... June 25, 2021 Women and girls in science: We won’t stop pushing for progress February 11, 2023 Innovative cancer spinouts: 3 new projects get green light August 13, 2021 Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... July 17, 2023 Load more HOT NEWS FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer Patient Guide in Hepatocellular Carcinoma Now Available Also in German Gentle regular exercise could reduce the risk of liver cancer in... New treatment for Waldenstrom’s macroglobulinaemia in England
